Journal
NATURE NANOTECHNOLOGY
Volume 2, Issue 12, Pages 751-760Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nnano.2007.387
Keywords
-
Funding
- NCI NIH HHS [CA119349] Funding Source: Medline
- NIBIB NIH HHS [R01-EB000244, EB 003647] Funding Source: Medline
Ask authors/readers for more resources
Nanotechnology has the potential to revolutionize cancer diagnosis and therapy. Advances in protein engineering and materials science have contributed to novel nanoscale targeting approaches that may bring new hope to cancer patients. Several therapeutic nanocarriers have been approved for clinical use. However, to date, there are only a few clinically approved nanocarriers that incorporate molecules to selectively bind and target cancer cells. This review examines some of the approved formulations and discusses the challenges in translating basic research to the clinic. We detail the arsenal of nanocarriers and molecules available for selective tumour targeting, and emphasize the challenges in cancer treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available